glp-1 drugs moa Video: Non-insulin injectable antidiabetic - agonists and amylinomimetics: Nursing pharmacology What is GLP-1 and Its

[DOI] [PubMed] [Google Scholar] 71.Longato E, Di Camillo B, Sparacino G, Tramontan L, Avogaro A, Fadini GP

This dual-action mechanism offers superior blood sugar control and weight loss benefits compared to previous treatments

McGowan, M.D., Ph.D., Julio Rosenstock, M.D., Marie T.D

Results Study population We identified 73,895 new users of GLP-1 receptor agonists and 113,207 new users of SGLT2 inhibitors (Table 1)

For comorbid metabolic diseases, such as diabetes and obesity, the use of GLP-1RAs generally does not increase cancer risk and may offer certain benefits

Using medications specifically for weight loss while breastfeeding comes with potential risks as well as benefits, and should be discussed closely with your healthcare provider